A portion of amino acids 281-414 was used as the immunogen for the IDH1 R132H antibody.
IDH1 R132H antibody binds to IDH1-mutated protein, but does not bind the wild-type IDH1 protein. IDH1 R132H point mutations are frequently seen in World Health Organization grade II and III gliomas and are believed to constitute an early step in tumorigenesis. IDH1 R132H can be used as a diagnostic marker to help differentiate infiltrating gliomas from gliosis, and as a prognostic marker for gliomas and secondary glioblastoma multiforme. IDH1 R132H antibody shows strong cytoplasmic staining and weaker nuclear staining in tumor cells with the R132H-mutated peptide. Diffuse staining of the fibrillary tumor matrix is also seen.
